Meta-analysis of secure randomised controlled trials of β-blockade to prevent perioperative death in non-cardiac surgery
Authors:
- Sonia BouriSBSonia Bouri
- Matthew James Shun-ShinMSMatthew James Shun-Shin
- Graham D ColeGCGraham D Cole
- Jamil MayetJMJamil Mayet
- Darrel P FrancisDFDarrel P Francis
Open Access
Abstract
Current European and American guidelines recommend the perioperative initiation of a course of β-blockers in those at risk of cardiac events undergoing high- or intermediate-risk surgery or vascular surgery. The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography (DECREASE) family of trials, the bedrock of evidence for this, are no longer secure. We therefore conducted a meta-analysis of randomised controlled trials of β-blockade on perioperative mortality, non-fatal myocardial infarction, stroke and hypotension in non-cardiac surgery using the secure data. The randomised controlled trials of initiation of β-blockers before non-cardiac surgery were examined. Primary outcome was all-cause mortality at 30 days or at discharge. The DECREASE trials were separately analysed. Nine secure trials totalling 10 529 patients, 291 of whom died, met the criteria. Initiation of a course of β-blockers before surgery caused a 27% risk increase in 30-day all-cause mortality (p=0.04). The DECREASE family of studies substantially contradict the meta-analysis of the secure trials on the effect of mortality (p=0.05 for divergence). In the secure trials, β-blockade reduced non-fatal myocardial infarction (RR 0.73, p=0.001) but increased stroke (RR 1.73, p=0.05) and hypotension (RR 1.51, p<0.00001). These results were dominated by one large trial. Guideline bodies should retract their recommendations based on fictitious data without further delay. This should not be blocked by dispute over allocation of blame. The well-conducted trials indicate a statistically significant 27% increase in mortality from the initiation of perioperative β-blockade that guidelines currently recommend. Any remaining enthusiasts might best channel their energy into a further randomised trial which should be designed carefully and conducted honestly.Keywords
This publication has 31 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Reducing cardiac risk in non-cardiac surgery: evidence from the DECREASE studiesEuropean Heart Journal Supplements, 2009
- The effects of perioperative β-blockade: Results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trialAmerican Heart Journal, 2006
- Effect of perioperative β blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trialBMJ, 2006
- Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: Rationale and design of the DECREASE-IV studyAmerican Heart Journal, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- The Effect of Bisoprolol on Perioperative Mortality and Myocardial Infarction in High-Risk Patients Undergoing Vascular SurgeryNew England Journal of Medicine, 1999
- Beneficial Effects from β-Adrenergic Blockade in Elderly Patients Undergoing Noncardiac SurgeryAnesthesiology, 1999
- The Effect of Heart Rate Control on Myocardial Ischemia Among High-Risk Patients After Vascular SurgeryAnesthesia & Analgesia, 1999
- Pharmacokinetic and Biopharmaceutic Aspects of Once Daily Treatment with Metoprolol CR/ZOK: A Review ArticleThe Journal of Clinical Pharmacology, 1990